Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cogent Biosciences (COGT – Research Report) and Moderna (MRNA – Research Report).
Cogent Biosciences (COGT)
In a report released today, Colleen M. Kusy from Robert W. Baird downgraded Cogent Biosciences to Hold, with a price target of $8.00. The company’s shares closed last Friday at $7.44.
According to TipRanks.com, Kusy is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cogent Biosciences with a $14.13 average price target, representing a 59.7% upside. In a report issued on February 23, Wedbush also maintained a Hold rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Moderna (MRNA)
In a report released today, Rajesh Kumar from HSBC downgraded Moderna to Sell, with a price target of $86.00. The company’s shares closed last Friday at $96.46.
According to TipRanks.com, Kumar is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $128.57 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on COGT:
- Cogent Biosciences price target raised to $18 from $15 at Needham
- Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
- Cogent Biosciences announces ‘positive’ Part 1b data from SUMMIT trial
- Cogent Biosciences Launches $225M Private Stock Sale
- Cogent Biosciences announces oversubscribed $225M private placement
